2eb3 › Citations

Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.

Yoshikawa S, Kukimoto-Niino M, Parker L, Handa N, Terada T, Fujimoto T, Terazawa Y, Wakiyama M, Sato M, Sano S, Kobayashi T, Tanaka T, Chen L, Liu ZJ, Wang BC, Shirouzu M, Kawa S, Semba K, Yamamoto T, Yokoyama S
Oncogene 32 27-38 (2013)
Related entries: 2eb2, 3ug1, 3ug2, 3vjn, 3vjo

Cited: 66 times
EuropePMC logo PMID: 22349823

Abstract

The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular tyrosine kinase (TK) domain. The non-small cell lung cancer (NSCLC)-associated EGFR mutants, L858R and G719S, are constitutively active and oncogenic. They display sensitivity to TK inhibitors, including gefitinib and erlotinib. In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants. In this study, our biochemical analyses revealed that the introduction of the T790M mutation confers gefitinib resistance on the G719S mutant. The G719S/T790M double mutant has enhanced activity and retains high gefitinib-binding affinity. The T790M mutation increases the ATP affinity of the G719S mutant, explaining the acquired drug resistance of the double mutant. Structural analyses of the G719S/T790M double mutant, as well as the wild type and the G719S and L858R mutants, revealed that the T790M mutation stabilizes the hydrophobic spine of the active EGFR-TK conformation. The Met790 side chain of the G719S/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands. In the L858R mutant structure, the active-site cleft is expanded by the repositioning of Phe723 within the P-loop. Notably, the introduction of the F723A mutation greatly enhanced the gefitinib sensitivity of the wild-type EGFR in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity. Taken together, our results provide a structural basis for the altered drug sensitivities caused by distinct NSCLC-associated EGFR mutations.

Articles - 2eb3 mentioned but not cited (10)

  1. Using reverse docking to identify potential targets for ginsenosides. Park K, Cho AE. J Ginseng Res 41 534-539 (2017)
  2. Diversity of Cultivable Microbes From Soil of the Fildes Peninsula, Antarctica, and Their Potential Application. Cong B, Yin X, Deng A, Shen J, Tian Y, Wang S, Yang H. Front Microbiol 11 570836 (2020)
  3. Molecular Docking Optimization in the Context of Multi-Drug Resistant and Sensitive EGFR Mutants. García-Godoy MJ, López-Camacho E, García-Nieto J, Nebro AJ, Aldana-Montes JF. Molecules 21 E1575 (2016)
  4. Statistical analysis of EGFR structures' performance in virtual screening. Li Y, Li X, Dong Z. J Comput Aided Mol Des 29 1045-1055 (2015)
  5. In silico bimolecular characterization of anticancer phytochemicals from Fagonia indica. Javed T, Raja SA, Rehman KU, Khalid S, Khalid N, Riaz S. Pak J Pharm Sci 34 883-889 (2021)
  6. Biochemical characterization, cytotoxic, antimutagenic, anticancer and molecular docking studies on Tecomella undulata. Riaz S, Javed MA, Nawaz I, Javed T. Saudi J Biol Sci 29 2421-2431 (2022)
  7. High-Resolution Structures of K+ Channels. Jiang QX. Handb Exp Pharmacol 267 51-81 (2021)
  8. A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition. Lenchner DS, Petrova ZO, Hunihan L, Ashtekar KD, Walther Z, Wilson FH. NPJ Precis Oncol 8 3 (2024)
  9. Design, synthesis, HER2 inhibition and anticancer evaluation of new substituted 1,5-dihydro-4,1-benzoxazepines. Cruz-López O, Ner M, Nerín-Fonz F, Jiménez-Martínez Y, Araripe D, Marchal JA, Boulaiz H, Gutiérrez-de-Terán H, Campos JM, Conejo-García A. J Enzyme Inhib Med Chem 36 1553-1563 (2021)
  10. Uncovering the Mechanism of Drug Resistance Caused by the T790M Mutation in EGFR Kinase From Absolute Binding Free Energy Calculations. Zhou H, Fu H, Liu H, Shao X, Cai W. Front Mol Biosci 9 922839 (2022)


Reviews citing this publication (16)

  1. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Juchum M, Günther M, Laufer SA. Drug Resist Updat 20 12-28 (2015)
  2. 'Latent drivers' expand the cancer mutational landscape. Nussinov R, Tsai CJ. Curr Opin Struct Biol 32 25-32 (2015)
  3. Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review). Li K, Yang M, Liang N, Li S. Oncol Rep 37 1347-1358 (2017)
  4. Mechanisms of apoptosis by the tumor suppressor Par-4. Hebbar N, Wang C, Rangnekar VM. J Cell Physiol 227 3715-3721 (2012)
  5. A historical perspective on protein crystallization from 1840 to the present day. Giegé R. FEBS J 280 6456-6497 (2013)
  6. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. Abourehab MAS, Alqahtani AM, Youssif BGM, Gouda AM. Molecules 26 6677 (2021)
  7. Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR). Kaufman NEM, Dhingra S, Jois SD, Vicente MDGH. Molecules 26 1076 (2021)
  8. Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer. Martin-Fernandez ML, Clarke DT, Roberts SK, Zanetti-Domingues LC, Gervasio FL. Cells 8 E316 (2019)
  9. Piecing it together: Unraveling the elusive structure-function relationship in single-pass membrane receptors. Valley CC, Lewis AK, Sachs JN. Biochim Biophys Acta Biomembr 1859 1398-1416 (2017)
  10. EGFR Mutations in Head and Neck Squamous Cell Carcinoma. Nair S, Bonner JA, Bredel M. Int J Mol Sci 23 3818 (2022)
  11. Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. Li MJ, He Q, Li M, Luo F, Guan YS. Onco Targets Ther 9 1291-1302 (2016)
  12. Stoichiometric Thiol Redox Proteomics for Quantifying Cellular Responses to Perturbations. Day NJ, Gaffrey MJ, Qian WJ. Antioxidants (Basel) 10 499 (2021)
  13. A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants. Guan H, Du Y, Ning Y, Cao X. Future Med Chem 9 693-704 (2017)
  14. Influence of Amino Acid Mutations and Small Molecules on Targeted Inhibition of Proteins Involved in Cancer. Kanakaveti V, Anoosha P, Sakthivel R, Rayala SK, Gromiha MM. Curr Top Med Chem 19 457-466 (2019)
  15. Looking lively: emerging principles of pseudokinase signaling. Sheetz JB, Lemmon MA. Trends Biochem Sci 47 875-891 (2022)
  16. Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review. Mansour MA, AboulMagd AM, Abbas SH, Abdel-Rahman HM, Abdel-Aziz M. RSC Adv 13 18825-18853 (2023)

Articles citing this publication (40)

  1. DOCK 6: Impact of new features and current docking performance. Allen WJ, Balius TE, Mukherjee S, Brozell SR, Moustakas DT, Lang PT, Case DA, Kuntz ID, Rizzo RC. J Comput Chem 36 1132-1156 (2015)
  2. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV. Nature 597 732-737 (2021)
  3. Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. Sogabe S, Kawakita Y, Igaki S, Iwata H, Miki H, Cary DR, Takagi T, Takagi S, Ohta Y, Ishikawa T. ACS Med Chem Lett 4 201-205 (2013)
  4. Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition. Choe C, Shin YS, Kim C, Choi SJ, Lee J, Kim SY, Cho YB, Kim J. Onco Targets Ther 8 3665-3678 (2015)
  5. Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Castillo-Pichardo L, Dharmawardhane SF. Nutr Cancer 64 1058-1069 (2012)
  6. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Liu M, Xu S, Wang Y, Li Y, Li Y, Zhang H, Liu H, Chen J. Oncotarget 7 84951-84964 (2016)
  7. A view on EGFR-targeted therapies from the oncogene-addiction perspective. Perez R, Crombet T, de Leon J, Moreno E. Front Pharmacol 4 53 (2013)
  8. Selective and reversible modification of kinase cysteines with chlorofluoroacetamides. Shindo N, Fuchida H, Sato M, Watari K, Shibata T, Kuwata K, Miura C, Okamoto K, Hatsuyama Y, Tokunaga K, Sakamoto S, Morimoto S, Abe Y, Shiroishi M, Caaveiro JMM, Ueda T, Tamura T, Matsunaga N, Nakao T, Koyanagi S, Ohdo S, Yamaguchi Y, Hamachi I, Ono M, Ojida A. Nat Chem Biol 15 250-258 (2019)
  9. Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors. Doss GP, Rajith B, Chakraborty C, NagaSundaram N, Ali SK, Zhu H. Sci Rep 4 5868 (2014)
  10. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong KK, Yarden Y, Casanova E, Soria JC, Colinge J, Siebel CW, Mazieres J, Favre G, Paz-Ares L, Maraver A. J Clin Invest 130 612-624 (2020)
  11. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity. Ai X, Sun Y, Wang H, Lu S. Amino Acids 46 1635-1648 (2014)
  12. A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations. Ryslik GA, Cheng Y, Cheung KH, Modis Y, Zhao H. BMC Bioinformatics 15 86 (2014)
  13. Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer. Li H, Stokes W, Chater E, Roy R, de Bruin E, Hu Y, Liu Z, Smit EF, Heynen GJ, Downward J, Seckl MJ, Wang Y, Tang H, Pardo OE. Cell Discov 2 16031 (2016)
  14. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Lara MS, Holland WS, Chinn D, Burich RA, Lara PN, Gandara DR, Kelly K, Mack PC. Clin Lung Cancer 18 281-285 (2017)
  15. Rational Design of a Dephosphorylation-Resistant Reporter Enables Single-Cell Measurement of Tyrosine Kinase Activity. Turner AH, Lebhar MS, Proctor A, Wang Q, Lawrence DS, Allbritton NL. ACS Chem Biol 11 355-362 (2016)
  16. Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC). Nagalakshmi K, Jamil K, Pingali U, Reddy MV, Attili SS. Biomarkers 19 198-206 (2014)
  17. Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1. Yoza K, Himeno R, Amano S, Kobashigawa Y, Amemiya S, Fukuda N, Kumeta H, Morioka H, Inagaki F. Genes Cells 21 1049-1058 (2016)
  18. Click chemistry based synthesis, cytotoxic activity and molecular docking of novel triazole-thienopyrimidine hybrid glycosides targeting EGFR. Khattab RR, Alshamari AK, Hassan AA, Elganzory HH, El-Sayed WA, Awad HM, Nossier ES, Hassan NA. J Enzyme Inhib Med Chem 36 504-516 (2021)
  19. EGFR gene regulation in colorectal cancer cells by garlic phytocompounds with special emphasis on S-Allyl-L-Cysteine Sulfoxide. Roy N, Nazeem PA, Babu TD, Abida PS, Narayanankutty A, Valsalan R, Valsala PA, Raghavamenon AC. Interdiscip Sci 10 686-693 (2018)
  20. Letter Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations. Panicker PS, Melge AR, Biswas L, Keechilat P, Mohan CG. Chem Biol Drug Des 90 629-636 (2017)
  21. Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. Brown BP, Zhang YK, Kim S, Finneran P, Yan Y, Du Z, Kim J, Hartzler AL, LeNoue-Newton ML, Smith AW, Meiler J, Lovly CM. Proc Natl Acad Sci U S A 119 e2206588119 (2022)
  22. Rational design of non-resistant targeted cancer therapies. Martínez-Jiménez F, Overington JP, Al-Lazikani B, Marti-Renom MA. Sci Rep 7 46632 (2017)
  23. Structural Basis for the Inhibition of Cyclin G-Associated Kinase by Gefitinib. Ohbayashi N, Murayama K, Kato-Murayama M, Kukimoto-Niino M, Uejima T, Matsuda T, Ohsawa N, Yokoyoma S, Nojima H, Shirouzu M. ChemistryOpen 7 721-727 (2018)
  24. Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer. Yu X, Wang T, Lou Y, Li Y. Mol Inform 35 25-35 (2016)
  25. Imaging analysis of EGFR mutated cancer cells using peptide nucleic acid (PNA)-DNA probes. Shigeto H, Ohtsuki T, Iizuka A, Akiyama Y, Yamamura S. Analyst 144 4613-4621 (2019)
  26. Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. Liu W, Ning JF, Meng QW, Hu J, Zhao YB, Liu C, Cai L. Drug Des Devel Ther 9 3837-3851 (2015)
  27. Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines. Sato M, Fuchida H, Shindo N, Kuwata K, Tokunaga K, Xiao-Lin G, Inamori R, Hosokawa K, Watari K, Shibata T, Matsunaga N, Koyanagi S, Ohdo S, Ono M, Ojida A. ACS Med Chem Lett 11 1137-1144 (2020)
  28. Analysis of Single Nucleotide-Mutated Single-Cancer Cells Using the Combined Technologies of Single-Cell Microarray Chips and Peptide Nucleic Acid-DNA Probes. Shigeto H, Yamada E, Kitamatsu M, Ohtsuki T, Iizuka A, Akiyama Y, Yamamura S. Micromachines (Basel) 11 E628 (2020)
  29. Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer. Ding X, Liu X, Song X, Yao J. Mol Inform 35 529-537 (2016)
  30. Detection of the EGFR G719S Mutation in Non-small Cell Lung Cancer Using Droplet Digital PCR. Esteva-Socias M, Enver-Sumaya M, Gómez-Bellvert C, Guillot M, Azkárate A, Marsé R, Sastre Ú, Blasco A, Calabuig-Fariñas S, Asensio VJ, Terrasa J, Obrador-Hevia A. Front Med (Lausanne) 7 594900 (2020)
  31. Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures. Guerin N, Feichtner A, Stefan E, Kaserer T, Donald BR. Cell Syst 13 830-843.e3 (2022)
  32. Design, Synthesis, Anticancer Activity and Molecular Docking of New 1,2,3-Triazole-Based Glycosides Bearing 1,3,4-Thiadiazolyl, Indolyl and Arylacetamide Scaffolds. Elganzory HH, Alminderej FM, El-Bayaa MN, Awad HM, Nossier ES, El-Sayed WA. Molecules 27 6960 (2022)
  33. Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations. Li M, Li M, Xie Y, Guo J. Molecules 27 3844 (2022)
  34. Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations. van Alderwerelt van Rosenburgh IK, Lu DM, Grant MJ, Stayrook SE, Phadke M, Walther Z, Goldberg SB, Politi K, Lemmon MA, Ashtekar KD, Tsutsui Y. Nat Commun 13 6791 (2022)
  35. Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer. Zhao ZT, Wang J, Fang L, Qian XD, Cai Y, Cao HQ, Wang GR, He ML, Jiang YY, Wang DG, Li YP. Acta Pharmacol Sin 44 244-254 (2023)
  36. Conformational stabilization of FOX-DNA complex architecture to sensitize prostate cancer chemotherapy. Chen B, Wang H, Wu Z, Duan B, Bai P, Zhang K, Li W, Zheng J, Xing J. Amino Acids 49 1247-1254 (2017)
  37. Letter Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report. Tu HY, Li YS, Yang JJ, Chen HJ, Jiang BY, Zhong WZ, Yang XN, Wu YL. Clin Drug Investig 41 483-488 (2021)
  38. Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells. Nie L, Wang YN, Hsu JM, Hou J, Chu YY, Chan LC, Huo L, Wei Y, Deng R, Tang J, Hsu YH, Ko HW, Lim SO, Huang K, Chen MK, Chiu TJ, Cheng CC, Fang YF, Li CW, Goverdhan A, Wu HJ, Lee CC, Wang WL, Hsu J, Chiao P, Wang SC, Hung MC. Am J Cancer Res 13 1209-1239 (2023)
  39. Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma. Lu H, Zhang B, Xie Y, Zhao W, Han W, Zhou L, Wang Z. Invest New Drugs 41 564-578 (2023)
  40. [Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report]. Wang X, Dong Y, Liang T, Zhang X, Ma K, Cui Y. Zhongguo Fei Ai Za Zhi 18 592-598 (2015)


Quick links